Interaction of cytosine arabinoside and lovastatin in human leukemia cells

Sarah A. Holstein, Raymond J. Hohl

Research output: Contribution to journalArticle

54 Scopus citations

Abstract

Cytosine arabinoside (ara-C) is widely used for the treatment of leukemias and displays significant toxicities. Lovastatin, an HMG-CoA reductase inhibitor, is extensively used to treat hypercholesterolemia. To determine whether lovastatin could augment ara-C's activity we have examined their effects in the human erythroleukemia K562 cell line and the ara-C resistant ARAC8D cell line. A synergistic interaction between the two drugs was found. We have demonstrated that the interaction does not occur at the level of RAS but may involve lovastatin's effect of downregulating MAPK activity and preventing ara-C-induced MAPK activation. These studies represent the first description of a potentially beneficial interaction between lovastatin and ara-C that could be applied to the treatment of human leukemia.

Original languageEnglish (US)
Pages (from-to)651-660
Number of pages10
JournalLeukemia Research
Volume25
Issue number8
DOIs
Publication statusPublished - Jun 11 2001

    Fingerprint

Keywords

  • Apoptosis
  • Cytosine arabinoside
  • HMG-CoA reductase
  • MAPK
  • RAS

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this